« on: April 29, 2015, 09:29:45 am »
Presented at the recent annual AAN conference in Washington, DC:
[P3.263] Experience with Long Term Rituximab Use in a Multiple Sclerosis Clinic
Megan Barra, Khac Huy Vo, James Stankiewicz
Brookline, MA, USA.
OBJECTIVE:
Examine efficacy, dosing, and safety of rituximab in a MS Clinical Cohort
BACKGROUND:
A successful phase II trial of Rituximab in MS has led to occasional off-label use. The safety and efficacy profile of Rituximab is not well established in a repeatedly dosed MS cohort.
DESIGN/METHODS:
MS patients at the Partners MS center who have received rituximab were identified. We have conducted a retrospective chart review of these patients. We have collected information on patient characteristics including MS type, rituximab dose and dates administered, relapses identified, CD19/20 counts and any safety related events.
RESULTS:
87 (38 RRMS, 13 PPMS, 36 SPMS) patients received one or more rituximab doses at our clinic. Longest duration of ongoing treatment was 5 years. Thirteen patients received a 500mg dose, the remainder 1g. No rituximab related deaths were reported. Efficacy and safety and CD19/20 data will be presented.
CONCLUSIONS:
Rituximab has been administered to many patients in our clinic. Further conclusions will be presented.
_________________
Category - MS and CNS Inflammatory Disease: Clinical Science
Session: P3: Poster Session III: MS and CNS Inflammatory Diseases: Treatment Efficacy, Safety and Tolerability (2:00 PM-6:30 PM)
Date/Time: Tuesday, April 21, 2015 - 2:00 pm
The abstract can be seen
here.
« Last Edit: May 13, 2015, 04:11:20 pm by agate »
MS Speaks--online for 17 years
SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.